VolitionRx Limited (NYSE American: VNRX) has highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter, discussing the implications of the test. Multiple studies have shown that the Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes including organ failure and mortality.
According to VolitionRx, most of the supporting research has been peer reviewed and published, with experts noting the consistency of findings across multiple countries and patient populations. The company believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies. For more details, the full press release is available at https://ibn.fm/2IH3m.
VolitionRx is a multi-national company focused on advancing epigenetics. Through its subsidiaries, it develops and commercializes simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. Further information is available on the company’s website at https://volition.com/.
The growing evidence supporting the Nu.Q NETs test underscores its potential to improve sepsis management globally. Sepsis remains a leading cause of death in hospitals, and early detection and monitoring are critical. VolitionRx’s technology could enable clinicians to identify patients at risk and tailor treatments accordingly. The consistency of findings across diverse populations strengthens the case for broader adoption. As the body of evidence expands, the test may become a standard tool in critical care, ultimately improving outcomes for patients with sepsis and other NETosis-related conditions.
